ABOUT BAPA

Our Mission

Advocate – Educate – Communicate

We strive to organize Bangladeshi-American Pharmacists in a strong and professional platform so they can be more successful in their career and have a fulfilling experience in this country. We work to get the members involved in the socio-political process that determines their future. We hope to motivate everyone to contribute their time and talent to the betterment of the pharmacy profession here at home and in Bangladesh.

Specifically, the purpose of the organization is to foster cooperation and collaboration among Bangladeshi pharmacists residing in North America; to build and maintain relations with other pharmacists’ associations in North America, to support the profession of pharmacy in Bangladesh and in North America; to support and encourage the development of Pharmaceutical Science in Bangladesh; to develop and conduct programs for maintaining and improving the professional standards; to promote welfare of members’ families in case of need; to protect the professional interests of members of the Association.

Our Sponsors

Silver Sponsor

Silver Sponsor

Silver Sponsor

Pharmaceutical News

  • Plastic bottles transformed into Parkinson’s drug using bacteria
    on March 20, 2026 at 9:00 am

    A drug to treat Parkinson’s disease can be made from waste plastic bottles using a pioneering method, a study shows. The approach harnesses the power of bacteria to transform post-consumer plastic into L-DOPA, a frontline medication for the neurological disorder.

  • Researchers break decades-old bottleneck in chemotherapy drug manufacturing
    on March 19, 2026 at 9:00 am

    An international team of researchers has achieved a breakthrough in the production of doxorubicin, a vital chemotherapy agent. The study identifies and resolves molecular "bottlenecks" that have limited the natural production of this drug for over 50 years. Doxorubicin is a chemotherapy drug that was first approved for medical use in the 1970s.

  • Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease
    on March 18, 2026 at 9:00 am

    The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of neurological manifestations of type 3 Gaucher disease (GD3), a rare lysosomal storage disorder.

  • Preclinical study reveals new cream may prevent or slow growth of some common skin cancers
    on March 17, 2026 at 9:00 am

    A topical cream activated the skin’s immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, according to a study published in the Journal of Clinical Investigation. Developed by researchers at the Perelman School of Medicine at the University of Pennsylvania, the cream works by blocking LSD1, an enzyme that suppresses immune‑activating pathways in the skin.

  • Safer blood clot treatment with apixaban than with rivaroxaban
    on March 16, 2026 at 9:00 am

    The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear winner: while both drugs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, with fewer bleeding complications. Venous thrombosis occurs when a blood clot lodges in the veins of the legs or lungs.